Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

A groundbreaking injectable medication has demonstrated remarkable effectiveness in reducing cholesterol levels, potentially ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

Other common causes can also affect insulin effectiveness.

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Tom Nolan reviews this week’s research Will cardiovascular disease prevention mostly be delivered by subcutaneous injection in the future? With increasing numbers of people starting tirzepatide and ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...